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Abstract
Objective: Increasing evidence has accumulated showing the role of APOBEC3G (A3G) and 3F (A3F) in the control of HIV-1
replication and disease progression in humans. However, very few studies have been conducted in HIV-infected children.
Here, we analyzed the levels of A3G and A3F expression and induced G-to-A hypermutation in a group of children with
distinct profiles of disease progression.
Methodology/Principal Findings: Perinatally HIV-infected children were classified as progressors or long-term non-
progressors according to criteria based on HIV viral load and CD4 T-cell counts over time. A group of uninfected control
children were also enrolled in the study. PBMC proviral DNA was assessed for G-to-A hypermutation, whereas A3G and A3F
mRNA were isolated and quantified through TaqManH real-time PCR. No correlation was observed between disease
progression and A3G/A3F expression or hypermutation levels. Although all children analyzed showed higher expression
levels of A3G compared to A3F (an average fold of 5 times), a surprisingly high A3F-related hypermutation rate was
evidenced in the cohort, irrespective of the child’s disease progression profile.
Conclusion: Our results contribute to the current controversy as to whether HIV disease progression is related to A3G/A3F
enzymatic activity. To our knowledge, this is the first study analyzing A3G/F expression in HIV-infected children, and it may
pave the way to a better understanding of the host factors governing HIV disease in the pediatric setting.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) infection in
children often progresses rapidly to acquired immunodeficiency
syndrome (AIDS). The majority of infected children under 15
years of age develop AIDS, and most die [1]. The risk of pediatric
disease progression in mother-to-child transmission (MTCT) has
been associated with different factors, such as mother with
advanced HIV-1 disease, as well as immunological, virological
and host-specific factors [2,3].
A new class of host restriction factors has been described to
play an important role in restricting intracellular viral replication.
Enzymes of the apolipoprotein B mRNA-editing catalytic
polypeptide (APOBEC) family convert cytidine to uridine in the
transient (2)ssDNA replication intermediate, which is later
reflected as G-to-A changes in the (+)strand [4,5,6,7]. As these
mutations usually occur at very high frequency in sequences, this
phenomenon is often called hypermutation. Dinucleotide motifs
within DNA are preferentially targeted by APOBEC3G (A3G)
and APOBEC3F (A3F), resulting in proviral DNA GG to AG and
GA to AA substitutions, respectively. A3G and A3F exhibit
potent anti-HIV-1 activity [8,9,10,11,12,13] and are expressed in
lymphocytes, the major target cells for HIV-1 infection [9,11].
HIV-1 Vif counteracts A3G/F by preventing their encapsidation
into virions and by inducing their proteossomal degradation in
the producer cell [14,15]. The effects of A3G/F proteins likely
modify both the efficiency of HIV-1 transmission and disease
progression [16], but their role in these processes is not well
understood.
A3G has been referred to as the major contributor to hypermuta-
tion in vivo and in vitro [12,13,17,18,19,20,21,22,23]. However,
depending on the HIV genomic region analyzed, varying effects of
A 3 Gc a nb ef o u n d .F o re x a m p l e ,h y p e r m u t a t i o na n a l y s e si nt h eH I V
protease (PR) region of the pol gene have indicated a proportionally
large number of G-to-A changes associated to A3F [24,25].
Evidence suggests that individuals who express high levels of
A3G mRNA tend to control the levels of HIV-1 viremia [26,27].
It has also been suggested that levels of A3G expression decrease
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24118with disease progression [28]. A recent study showed that the
frequency of hypermutated viral genomes in elite suppressors was
not significantly different from that observed in patients on highly
active antiretroviral therapy (HAART), and no correlation was
found between A3G expression and the rate of hypermutation
[20]. Differently from the previous report, the level of
hypermutation was correlated with A3G expression in other
studies [28,29].
In the present study, we analyzed A3G and A3F mRNA
expression levels, as well as G-to-A hypermutation contexts in
HIV-1 proviral protease sequences from infected children with
different profiles of disease progression.
Methods
Ethics Statement
All parents/guardians of the children read and signed an
informed consent to participate to this study. This study was
approved by the Institutional Review Board of the Federal
University of Rio de Janeiro.
Patients and Samples
Seventeen HIV-1-infected children with different profiles of
disease progression regularly followed-up at the Pediatric Unit of
Federal University of Rio de Janeiro since birth were enrolled in
Table 1. Demographic and clinical characteristics of HIV-infected children under study.
Patient ID Age*
Treatment
experience* CDC classification* Follow-up Data Sample Data
Period
Highest log
HIV-1 VL
Lowest
CD4 T-cell% Date
Log HIV-1
VL
CD4
+
T-cell%
N35/LTNP 10.2 No A1 1994–2003 4.59 28 04/2003 3.73 27
N52/LTNP 10.6 Yes A1 1992–2002 4.88 27 11/2002 3.88 33
N64/LTNP 11.3 No A1 1993–2004 4.40 31 05/2003 4.08 33
N70/LTNP 13.7 No A1 1996–2004 4.30 30 11/2003 4.34 32
N72/LTNP 7.7
# No N1 2000–2007 2.58 29 12/2003 2.23 30
N82/LTNP 6.8
# No N1 1998–2007 4.91 33 07/2004 4.85 34
N48/P 6.3 Yes A3 2001–2004 4.28 17 02/2004 3.64 19
N58/P 5.8 No A2 2000–2004 5.49 15 07/2003 5.49 25
N59/P 5.6 Yes A2 2000–2005 5.04 5 09/2003 4.75 14
N61/P 12.2 Yes A2 1998–2004 4.77 15 02/2003 2.86 23
N67/P 8.2 Yes B2 1999–2005 5.28 10 04/2004 2.34 10
N75/P 6.8 Yes B2 2000–2004 5.15 19 08/2003 1.96 22
N25/P 3.4 Yes C3 2001–2003 6.45 1 06/2003 5.26 19
N27/P 3.0 Yes C3 2001–2003 6.41 9 10/2002 5.30 15
N28/P 3.3 Yes C3 2001–2003 6.97 6 09/2002 5.79 24
N33/P 3.0 Yes C3 2001–2003 7.53 4 12/2003 4.83 35
N62/P 1.9 Yes B3 2002–2003 5.49 6 12/2002 5.23 8
*At sample collection.
#Both patients had CD4%.25% at the age of 8 years old.
doi:10.1371/journal.pone.0024118.t001
Table 2. Frequency of G-to-A hypermutation in HIV-1-infected children with distinct profiles of disease progression.
PATIENT
GROUP
NO. OF
PATIENTS
NO. OF
CLONES HYPERMUTATION (%) AVERAGE G-to-A CONTEXT (%)
Patients Clones GG (A3G)
GA
(A3F)
LTNP 6 60 3 1 (10) 50 0
1 (10) 37 83
1 (10) 39 91
Total 6 60 50% 10% 42% 58%
P 11 121 3 2 (20) 35 5
6 (60) 26 86
1 (10) 32 13
Total 11 121 27% 30% 31% 35%
doi:10.1371/journal.pone.0024118.t002
APOBEC3G/F Expression in HIV
+ Children
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+ T-cell
counts and HIV-1 viral load at every 3–4 months, were retrieved
from a previous prospective study. All patients have been infected
perinatally and therefore had known time of infection. Stored
peripheral blood mononuclear cell (PBMC) samples were thawed
and used for mRNA and proviral DNA extraction (see below). Six
children were classified as long-term nonprogressors (LTNP),
defined as over 8 years of age, with CD4$25%, and under no
antiretroviral therapy, a well-accepted definition for pediatric
patients [30]; the remaining children (11 patients) were classified
as typical progressors. Demographical, clinical, laboratory and
follow-up data for all pediatric patients are summarized in Table 1.
For A3G and A3F expression level determination, nine samples of
HIV-negative children (NC) from the same previous study were
used as a negative control group to assess A3G/F expression in the
absence of HIV infection.
HIV proviral DNA hypermutation
Genomic DNA from PBMC was isolated using the Illustra
Blood GenomicPrep Mini Spin Kit (GE Healthcare). Nested PCR
was then performed to amplify the HIV-1 proviral protease (PR)
genomic region corresponding to HXB2 coordinates 2268–2564,
as previously described [31]. HIV PR region was chosen because
the first half of the pol gene is a highly frequent target of
hypermutation-associated changes [21,23,32]. PCR-amplified
products were cloned into pMOSBlue Blunt-ended PCR cloning
kit (GE Healthcare) and a minimum of 10 clones from each
patient were isolated by colony PCR and sequenced, therefore
providing a sensitivity of 10% for detecting hypermutated
sequences. Hypermutation was quantified using Hypermut 2.0
[33]. A sequence was considered hypermutated when the p-value
was #0.05 in the Fisher’s exact test that compared the number of
G-to-A mutations by A3G/F versus a control context. In order to
avoid overestimation of hypermutation by comparing different
viral strains, we have used the plasma-derived genomic viral
sequence generated by RT-PCR, representative of each patient’s
circulating virus, as the control context. We have also used the
HIV-1 clone HXB2 as a reference for context in Hypermut for
comparison of results. All patients were infected with HIV-1
subtype B viruses, as determined by phylogenetic analysis (not
shown). All plasma-derived bulk sequences and proviral clonal
sequences analyzed were submitted to the GenBank sequence
database and were assigned the accession numbers JF950037 to
JF950234.
APOBEC3G and 3F mRNA expression analyses
Patient’s PBMC also had their RNA extracted and purified for
A3G and A3F mRNA expression analyses through TaqManH-
based real time PCR. Total RNA was extracted with TrizolH,
precipitated with lithium chloride and quantified in a NanodropH
apparatus. Two micrograms of RNA were subject to cDNA
synthesis with Superscript RT and oligo-d(T) (Invitrogen, CA). For
a subset of the samples, we have also primed the RT reactions with
random hexameric primers, using the same amount of RNA.
Primers and probes for A3G, A3F and the internal control
GAPDH were synthesized through the Assay-on-Demand
TM
(Applied Biosystems). Real time PCR reactions were conducted
in an ABI 7500 apparatus (Applied Biosystems) in triplicate and
with three different dilutions for each sample for determination of
the reaction efficiency. Only reactions with efficiency superior to
95% were used in the calculations. Results were expressed as the
relative number of A3G or A3F mRNA copies per 10
4 copies of
GAPDH mRNA.
Statistical analyses
Demographic and laboratory data (CD4
+ T-cell counts and
HIV viral load) were compared among the two patient groups
(typical progressors versus non-progressors) using Student’s t tests,
whereas for A3G and A3F expression level comparisons the
Mann-Whitney U test was used. The definition of HIV-1
hypermutated sequences conducted in Hypermut was implement-
ed within the software package using Fisher’s exact tests. We have
also compared A3G and A3F mRNA expression levels between
patients for which hypermutation was detected and those with no
hypermutation. Finally, we have stratified patients according to
HIV viral load levels (below and above 10,000 copies/ml) and
according to their treatment status (treatment-naı ¨ve or experi-
enced), and compared the groups with respect to A3G/F
expression. Calculations were performed in StatsDirect v.2.7.2
[34]. In all cases, p-values were considered significance at the
#0.05 level.
Results
Demographic and clinical characteristics of the HIV-infected
children analyzed in this study are depicted in Table 1. Among the
LTNP children, the lowest CD4
+ T-cell percentage values during
all time of follow-up ranged from 27 to 33%, whereas for
progressors they ranged from 1 to 19%. The average age of the
groups at the time of sample collection was 10.0 for LTNP and 5.4
for progressors (p=0.005). As expected, CD4
+ counts were higher
among LNTP (p,0.001) when compared with the progressor
group, but there was no difference in HIV viral load between the 2
groups (p=0.50). Children of the negative control group (NC)
averaged 4.7 years of age, ranging from 0.1 to 11.2 years (not
shown).
APOBEC3G and 3F G-to-A hypermutation events in HIV
proviral sequences were examined in the two disease progression
groups of HIV-infected children. An alignment of all proviral clonal
sequences referenced by their respective plasma viral bulk sequence
can be seen in Figure S1. Hypermutated proviral sequences were
detected more frequently among LTNP patients (50%) when
compared with the P group (27%) (Table 2 and Figure S1), yet this
difference was not statistically significant. Although less frequently,
the percentage of clones with hypermuted sequences was higher in
the P group patients. Results obtained using HXB2 instead of the
patient’s consensus plasma HIV sequence as reference for
hypermutation determination were not significantly different (not
shown). We could not find a clear correlation between hypermuta-
tion and the different patterns of disease progression. In both
groups, the most frequent changes were GA to AA, surprisingly
indicating a predominance of A3F-associated hypermutation
(Table 2 and Figure S1). The hypermutated clonal viral sequence
with the lowest p-value (higher significance) obtained in Hypermut
from all patients had evidence of simultaneous A3G and A3F
activity with the exception of sample N52-5, for which only A3G
activity was detected (Figure S1).
We next investigated whether the G-to-A hypermutation
changes were related to the levels of A3G and A3F mRNA
expression. All patient samples with detected hypermutation
Figure 1. APOBEC3G (A) and APOBEC3F (B) mRNA expression levels relative to GAPDH mRNA copy numbers of patients with or
without evidenced hypermutation. Horizontal bars depict the median value for each group.
doi:10.1371/journal.pone.0024118.g001
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children with no signs of hypermutation, were selected for
expression analysis. In all samples, A3G expression was higher
than that of A3F (p,0.0001; Mann-Whitney U test), with fold
variations ranging from 5 to 30 X (Figures 1A and B). Levels of
both A3G and A3F expression did not differ significantly when
comparing subjects with detected hypermutation with those where
no hypermutation was detected (p=0.84 and 0.66 for A3G and
A3F, respectively; Mann-Whitney U test).
We wanted to further assess whether A3G and A3F expression
levels were correlated with disease progression in HIV
+ children.
Nine samples of uninfected children were used as a negative
control (NC) group. Results for A3G and A3F expression in each
group are depicted in Figures 2A and B, respectively. There was
no clear correlation between both A3G and A3F expression and
disease progression in any group comparison done. Of note, when
median A3G expression values were compared among groups, we
found LTNP to be the highest A3G expressers (360062131/10
4
cp GAPDH), followed by progressors (262661809) and NC
(104962302). In our casuistic, the three highest A3G-expressing
uninfected children had median expression values significantly
higher than the median of the remaining NC (p=0.02; Mann-
Whitney U test). With respect to A3F expression, the progressors
group was the higher expresser (2706113/10
4 cp GAPDH),
followed by LTNP (2436148) and NC (1576134). However, none
of the median expression values was significantly different when
the disease progression groups were compared. Of interest, we also
failed to detect a significant correlation between A3G and A3F
expression levels in both HIV
+ and NC children groups (data not
shown; R
2=0.16 and 0.03, respectively).
Recent reports have indicated that A3F mRNA expression
levels might be largely underestimated when one uses oligo-d(T)-
primed cDNA synthesis, due to the presence of repetitive elements
in the long 39 untranslated region of its mRNA [35]. To test for
that possibility, we have subjected a subset of our patient’s samples
to random hexameric primer-based cDNA synthesis, which is
reported to be more efficient under these circumstances [35].
Total RNA from plasma of 6/11 progressors, 2/6 nonprogressors
and 5/9 HIV-negative controls were re-synthesized with random
primers and subject to the same mRNA A3G and A3F
quantification protocol. Indeed, the fold difference between A3G
and A3F changed significantly, with an average fold difference of
5x more A3G compared to A3F (range 2–9X) (Figure 3), as
opposed to the 15x fold difference seen with oligo-d(T)-primed
reactions. These results suggest that A3F mRNA levels were
underestimated in the previous experiments. However, the new
procedure did not change the relative profiles of A3G and A3F
expression among different groups, with HIV
+ subjects displaying
higher expression levels than negative controls (data not shown).
The differences observed between groups were not statistically
significant, as in the previous experiments.
We finally assessed the effect of antiretroviral treatment and of
the HIV-1 viral load levels on A3G/F mRNA expression in our
casuistic. When children were categorized in treated versus
untreated, irrespective of their disease progression profile, there
were no significant differences in the levels of either A3G or A3F
mRNA expression levels (Figure 4A; p=0.80 and 0.16, respec-
tively). Children with low HIV VL (below 10,000 copies/ml) also
did not show different levels of A3G/F expression when compared
to those with VL above that cut-off (Figure 4B; p=0.25 and 0.71,
respectively).
Discussion
Previous studies have addressed G-to-A hypermutation and
APOBEC3G sequence variations on disease progression in
infected children [36,37]. Our study, however, describes for the
first time the analysis of APOBEC3G and 3F mRNA expression
levels in an infected pediatric setting. Here, we investigated
whether hypermutation and APOBEC expression were associated
with different patterns of disease progression in this small cohort of
pediatric patients.
We were unable to correlate HIV hypermutation levels to
disease progression in children. Although our study has included a
small number of individual proviral sequences from each patient,
the lack of correlation between delayed disease progression and
hypermutation found here is in agreement with recent findings in
adults. Gandhi et al. found no correlation between hypermutation
in elite suppressors when compared to that in HIV
+ patients
undergoing HAART, after analyzing a large number of HIV-1
sequences [20]. This observation suggests that hypermutation
levels are not directly related to the intrinsic control of viremia
seen in LTNP. Indeed, we found one LNTP child with low HIV
viral load (3.73 log
10/mL of plasma) in which no hypermutation
was detected. Conversely, two samples from progressors, with
hypermutated sequences, had HIV VL over 5 log10/mL. Our
results further suggest a lack of correlation between HIV VL and
hypermutation (data not shown). While some other reports have
Figure 2. APOBEC3G (A) and APOBEC3G (B) mRNA expression levels relative to GAPDH mRNA copy numbers of patients with
different profiles of HIV disease progression. Horizontal bars depict the median value for each group.
doi:10.1371/journal.pone.0024118.g002
Figure 3. Average APOBEC3G to APOBEC3F mRNA expression
levels quantified from eight HIV
+ children (6 progressors and 2
nonprogressors) and five HIV
2 controls. A3F expression levels
were arbitrarily set at 1.
doi:10.1371/journal.pone.0024118.g003
APOBEC3G/F Expression in HIV
+ Children
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hypermutation [29,38] or to A3G expression levels [20,26,27,39]
in adults, different studies showed correlation between A3G
mRNA expression or G-to-A hypermutation and disease progres-
sion [28,32], and this issue is warranted further investigation.
Of interest, we have found a high contribution of A3F-mediated
hypermutation in the HIV-1 PR pol genomic region of viruses
from our children, a finding previously reported in infected adults.
A recent study by Armitage et al. has shown that, whereas A3G
hypermutates HIV proviruses roughly evenly across the genome,
A3F promotes higher numbers of changes at definite regions, the
largest being the pol PR region [23]. Indeed, A3F-mediated
hypermutation in HIV PR has been previously described [9,24].
These observations might explain, at least in part, the relatively
high observation of A3F-mediated hypermutation events in our
patients.
A re-analysis of A3G and A3F expression levels with random
primed-cDNA synthesis in a subset of HIV
+ and negative control
children for which cellular RNA was still available showed that the
A3F levels were underestimated, with fold differences to A3G
levels three times lower than those estimated with oligo-d(T)-
primed reactions. This is in agreement with data of Refsland et al.
[35], which suggest that the long A3F mRNA 39UTR presents
repetitive elements that can impair oligo-d(T)-primed cDNA
synthesis. Moreover, our confirmatory results further corroborate
the importance of A3F-mediated hypermutation in the pediatric
cohort studied.
Cho et al. have previously reported a positive correlation between
the expression of A3G and A3F in adults [39]. In our pediatric
casuistic, we failed to detect such correlation, both in HIV
+ and in
uninfected children. It is plausible that the differences observed
between their study and ours are related to the age groups analyzed.
Children’s immune systems are not completely developed, and HIV
infection during development may also impair specific immune
components. A3G and A3F expression levels might not correlate
well in a partially-developed immune system. In this view, it has
been shown that distinct CD4
+ T-helper lymphocyte subtypes show
differences in the levels of A3G expression [40]. Th1 effector cells
express higher levels of A3G and A3F mRNA, and of A3G proteins,
than Th2 cells. In addition, HIV-1 virions produced in Th1 cells
carry increased amounts of incorporated A3G compared to those
produced in Th2 cells [40]. As a result of lower ratios of CD4
+ Th1
cells observed in children compared to adults [41], children might
have a proportionally higher A3F-mediated hypermutation activity.
Finally, differential expression of the A3 proteins has been shown in
different human tissues [35]. In particular, tissues such as the
thymus and the spleen, which carry a large amount of T cells, and
have significantly different activities in children and adults, can
explain discrepancies in the levels of A3G and A3F seen in both
groups.
We cannot rule out the possibility that differences in A3G and
A3F protein activity are due to amino acid polymorphisms, to
protein stability or to differential interaction with Vif taking place
in the individuals analyzed here. Indeed, a number of Vif
mutants have been recently shown to lack A3G-counteracting
activity, and even interfere with wild type Vif molecules [42].
Conversely, amino acid changes in several A3 coding regions,
including A3G and A3F, also alter susceptibility to HIV-1 Vif
[43,44]. Additional studies in the A3G and A3F coding sequences
will improve our understanding of the role of each protein in
hypermutation. At the protein level, it is recognized that A3G
exists in two forms within cells, aggregated into low (LMM) or
high molecular mass (HMM) complexes [45]. While the first form
is active in virus deamination, the second is inactive. It has been
shown that selected cytokines, like IL-2, IL-7 and IL-15, induce a
shift of A3G into HMM complexes, rendering CD4
+ T-cells more
permissive to HIV infection. Other cytokines, such as TNFa,
upregulate A3G in cells but leave them in LMM complexes,
active against HIV [45]. Again here, differences in the immune
system of children compared to that of adults might account for
discrepancies in the amount of enzymatically-active forms of A3
proteins.
Another important issue to be considered here is the fact that
many different A3 proteins display anti-HIV activity, as reviewed
by Albin and Harris [46]. Although A3G and A3F have been
recognized as major players in HIV restriction, other members of
the APOBEC family such as A3DE and A3H have been shown to
harbor anti-HIV activity, as well as sensitivity to lentiviral Vif
proteins [43,46,47]. In this scenario, we cannot rule out the
possibility that other A3 proteins with similar target contexts to
A3F, particularly A3H [48,49], are contributing to the higher non-
A3G-mediated hypermutation seen herein.
Previous studies have reported higher levels of A3G expression
in subjects infected by HIV or HCV compared to uninfected
individuals [27,50]. Our results are in agreement with those
studies, and extend this observation to A3F. In our control group,
however, the three highest A3G-expressing uninfected children
had median expression values significantly higher than the median
of the remaining NC, suggesting that A3G expression may vary
substantially between individuals depending on various unrelated
infections and on other immunological factors. It has been recently
shown that infection by influenza A virus upregulates A3G, but
not A3F expression in infected cells [51]. Therefore, the possibility
that varying, unrecognized clinical conditions might alter A3G
expression levels in individuals cannot be ruled out, and may
prevent the establishment of clear associations between HIV
infection and A3G expression.
We failed to observe any association between HIV VL or
treatment experience and A3G/F mRNA expression in our
patients. This is agreement with the report by Ulenga et al., which
were not able to correlate hypermutation with VL in infected
adults [29]. A previous report failed to find differences in A3G-
mediated hypermutation between patients with undetectable VL
by natural means (among elite supressors) or with the use of
antiretroviral therapy [20], indicating that treatment per se does not
influence A3G expression levels. Further studies are warranted to
define specific biological or chemotherapeutical circumstances
under which APOBEC expression is modulated.
Overall, we were unable to find any correlations between A3G
or A3F expression levels, A3G- or A3F-induced hypermutation
and disease progression profiles in HIV-infected children. This is
however, to the best of our knowledge, the first study of A3G and
A3F mRNA expression conducted in pediatric HIV/AIDS
patients. The study of different disease progression profiles in the
pediatric setting is also worth mentioning. Interestingly, we found
evidence of a more pronounced A3F activity, not previously
reported in adults, that merits further investigation. We believe
this study helps contributing to a better understanding of the role
of restriction factors and host genetics in an infectious disease
pediatric setting.
Figure 4. APOBEC3G and APOBEC3F mRNA expression levels relative to GAPDH mRNA copy numbers comparing patients stratified
according to antiretroviral treatment exposure (A) and HIV viral load (B). Horizontal bars depict the median value for each group.
doi:10.1371/journal.pone.0024118.g004
APOBEC3G/F Expression in HIV
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Figure S1 HIV-1 protease nucleotide alignments of bulk and
clonal proviral sequences of each patient analyzed in the study.
The bulk sequence of each patient is used as a reference at the top
of each alignment. Dots represent nucleotide identities.
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